TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Lupin Limited ( (IN:LUPIN) ) just unveiled an update.
Lupin Limited has entered into a strategic License and Supply Agreement with Zentiva for the commercialization of its biosimilar Certolizumab Pegol across multiple international markets, excluding Australia, Japan, Brazil, Philippines, and India. Under the agreement, Lupin will handle development, manufacturing, and supply, while Zentiva will manage commercialization in Europe and CIS markets. The collaboration involves a non-refundable payment from Zentiva to Lupin, with profits shared between the companies, enhancing Lupin’s market reach and operational capabilities in the biosimilar segment.
More about Lupin Limited
Lupin Limited is a prominent player in the pharmaceutical industry, focusing on the development, manufacturing, and marketing of a wide range of generic and branded formulations. The company is known for its strong presence in the global pharmaceutical market, particularly in the areas of cardiovascular, diabetology, asthma, pediatrics, CNS, GI, anti-infective, and NSAID segments.
Average Trading Volume: 36,216
Current Market Cap: 903.1B INR
For a thorough assessment of LUPIN stock, go to TipRanks’ Stock Analysis page.